Interestingly, a combination of mutations in KMT2C, BCOR and KDM5C (i.e., NSCLC with mutation in any one of the three genes regarded as KMT2C/BCOR/KDM5C mutation positive) further improve the efficiency on ICB response prediction (OR 3.84, 95% CI 2.14∓6.89, p = 1.16 × 10−4) (Figure 1B). This evidence concerns the gene KDM5C and non-small cell lung carcinoma.